Q1 2023 Knight Therapeutics Inc Earnings Call Transcript
Good morning, and welcome to the Knight Therapeutics First Quarter 2023 Results Conference Call. (Operator Instructions) Please note this event is being recorded.
I would now like to turn the conference over to Samira Sakhia. Please go ahead.
Thank you, Debbie. Good morning, everyone, and welcome to Knight Therapeutics First Quarter 2023 Conference Call. I'm joined on today's call with Amal Khouri, our Chief Business Officer; Arvind Utchanah, our Chief Financial Officer; and Jeff Martens, our Global VP of Commercial.
I'm excited to report an impressive first quarter results with revenues of over $82 million and a 29% growth compared to the same period last year and record adjusted EBITDA of over $18 million, representing growth of 37% compared to the same period last year. This strong performance is a testament to the hard work and dedication of our team and the continued success of our portfolio across all of our therapeutic areas.
In addition to the continued
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |